The latest biotech news

News and Trends 19 Oct 2017

Personalized Breast Cancer Treatment Coming Soon with Help from Spanish Biotech

Inbiomotion has published the results of a Phase III study looking at its MAFTest to personalized approaches to the disease. Inbiomotion, based in Barcelona’s biotech hub, works on a highly selective biomarker for breast cancer. A Phase III study demonstrated that breast cancer patients that would benefit from zoledronic acid therapy can be selected, helping clinicians offer […]

October 19, 2017 - 3 minutesmins - By Alex Dale

News and Trends 19 Oct 2017

Dutch Biotech plans Pivotal Clinical Trial with First Gene Therapy for Hemophilia

uniQure is getting ready to start a Phase III clinical trial in 2018 with a new version of its gene therapy for hemophilia B. uniQure has officially launched a plan to bring the first gene therapy for hemophilia to the market. After multiple meetings with the FDA and the EMA, the Dutch biotech has received permission […]

October 19, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 19 Oct 2017

The FDA Approves a Second CAR-T Therapy, Cheaper than Novartis’

Gilead’s CAR-T cell therapy Yescarta has been approved by the FDA, making it the first competitor for Novartis’ CAR-T Kymriah. Yescarta (axicabtagene ciloleucel, or axi-cel for short) has become the second CAR-T therapy to be approved in the US. The FDA has authorized its use to treat aggressive B-cell non-Hodgkin lymphoma in patients for whom at least two […]

October 19, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 19 Oct 2017

Meet some of the Hottest Startups of 2017!

– This article was originally published on 27th September 2017. This is an updated version – Large events, like BIO-Europe offer startup slams, which give entrepreneurs the opportunity to present their company at the conference. Not only does a slam create exposure for the startup, but it also allows young companies to receive valuable feedback from […]

October 19, 2017 - 7 minutesmins - By External Contributor

News and Trends 19 Oct 2017

Austrian Researchers Identify Target for Treatment of Multiple Sclerosis

Multiple sclerosis is the most common disease of the CNS in young adults. Researchers may have stumbled across a new approach for its treatment. Researchers at the Medical University of Vienna have identified a target for the treatment of multiple sclerosis (MS). The research, published in the Journal of Autoimmunity, found that histone deacetylases (HDACs) play […]

October 19, 2017 - 3 minutesmins - By Alex Dale

News and Trends 18 Oct 2017

Eli Lilly Offers German Biotech up to €1.5Bn to Develop mRNA Cancer Vaccines

CureVac will be working with pharma giant Eli Lilly in the development of up to five cancer vaccines based on mRNA technology. Eli Lilly will pay CureVac $50M (€43M) upfront and invest €45M in equity to kick off a collaboration for the development and commercialization of up to five mRNA vaccines for cancer. CureVac could receive up […]

October 18, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 18 Oct 2017

German Researchers Set the Immune System Free to Fight Against Cancer

There could be a way to stop cancers escaping from the immune system, and researchers hope to use this for more effective cancer treatments. Researchers at Universität Bonn have found a way to “release the brakes” in the immune system that helps cancers to survive. Cancers benefit from this by pretending to be regular cells, […]

October 18, 2017 - 2 minutesmins - By Alex Dale

OncoDNA Biosequence Moncodaneum Cancer Big Data

News and Trends 18 Oct 2017

Belgian Biotech Gathers Major Oncology Centers to Tackle Cancer with Big Data

OncoDNA is gathering prestigious oncology centers to take part in Moncodaneum, an international project to bring precision medicine to cancer patients. The Belgian biotech OncoDNA has announced that it will be collaborating with the Strasbourg University Hospital, France, and the Oncology Center of Bydgoszcz, Poland, in the advancement of precision medicine for cancer. The two […]

October 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 18 Oct 2017

Biotech Crosses the Channel to Raise €9.7M for its Diagnostics Tools

Novacyt will use the money raised on the AIM market, London, to expand its manufacturing capacity and continue research looking into new techniques. Novacyt specializes in diagnostic tools for a number of indications, including cancer and infectious diseases. Today, it has announced that it has raised €9.7M by placing stocks on the London-based Alternative Investment Market (AIM). […]

October 18, 2017 - 2 minutesmins - By Alex Dale

News and Trends 17 Oct 2017

Swedish Human Cell Atlas gets the Support of Chan & Zuckerberg

The Human Cell Atlas will map all of the cells in the body, and the Chan Zuckerberg Initiative has given a grant to Swedish researchers to join the project. Mark Zuckerberg and his wife, Priscilla Chan, founded the Chan Zuckerberg Initiative to provide resources for projects, including biomedical research. The Initiative supports the Human Cell Atlas, an exciting […]

October 17, 2017 - 3 minutesmins - By Alex Dale

News and Trends 17 Oct 2017

Genfit Gets €180M Cash Injection to Bring its Pipeline to Market

Elafibranor, Genfit’s lead candidate, will continue its march towards the market with the added boost of massive financial support. Genfit is a leader in the development of diagnostic tools and therapeutics for metabolic and inflammatory diseases. Its lead candidate, elafibranor, targets Non-Alcoholic Stato-Hepatitis (NASH) – an inflammatory disease of the liver. The company has raised €180M by selling bonds […]

October 17, 2017 - 3 minutesmins - By Alex Dale

dupilumab inflammation regeneron sanofi 1

News and Trends 16 Oct 2017

Biotech Power-Couple Sees Positive Phase II Results For Inflammatory Disease Drug

Regeneron and Sanofi’s drug, dupilumab, has met primary and secondary endpoints for the treatment of eosinophilic esophagitis. The biotech-biopharma giants have announced that their candidate, Dupilumab, demonstrated good efficacy during a Phase II trial. The drug is designed for use against eosinophilic esophagitis, a nasty inflammatory disease of the esophagus that makes it difficult to swallow. […]

October 16, 2017 - 3 minutesmins - By Alex Dale

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Personalized Breast Cancer Treatment Coming Soon with Help from Spanish Biotech

Dutch Biotech plans Pivotal Clinical Trial with First Gene Therapy for Hemophilia

The FDA Approves a Second CAR-T Therapy, Cheaper than Novartis’

Meet some of the Hottest Startups of 2017!

Austrian Researchers Identify Target for Treatment of Multiple Sclerosis

Eli Lilly Offers German Biotech up to €1.5Bn to Develop mRNA Cancer Vaccines

German Researchers Set the Immune System Free to Fight Against Cancer

Belgian Biotech Gathers Major Oncology Centers to Tackle Cancer with Big Data

Biotech Crosses the Channel to Raise €9.7M for its Diagnostics Tools

Swedish Human Cell Atlas gets the Support of Chan & Zuckerberg

Genfit Gets €180M Cash Injection to Bring its Pipeline to Market

Biotech Power-Couple Sees Positive Phase II Results For Inflammatory Disease Drug

Subscribe to our newsletter to get the latest biotech news!